# Maralixibat in Patients With Cystic Fibrosis and Constipation

> **NCT06413368** · PHASE2,PHASE3 · RECRUITING · sponsor: **Children's Hospital Los Angeles** · enrollment: 20 (estimated)

## Conditions studied

- Constipation Chronic Idiopathic
- Cystic Fibrosis

## Interventions

- **DRUG:** Maralixibat 9.5 MG/ML [Livmarli]

## Key facts

- **NCT ID:** NCT06413368
- **Lead sponsor:** Children's Hospital Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413368, "Maralixibat in Patients With Cystic Fibrosis and Constipation". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06413368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*